About AREVA Med
AREVA Med is an AREVA subsidiary specializing in the development of innovative new therapies to fight cancer.
How it works
Learn how the nuclear therapy works, what is lead-212 (212Pb), and about our ongoing research.
The Phase I clinical trials of lead-212 is currently taking place in the United States.
News & Materials
Read about the latest news and events, and download brochures and fact sheets.
Macrocyclics, part of AREVA Med, is the global leader in chelating agent technologies for medicine.
AREVA Med launches production of lead-212 at new facilityRead more
AREVA Med – Roche Partnership: the common research laboratory aiming to develop new radio-immunotherapy treatments for cancer is operationalRead more